Efficacy and Safety of Pimodivir Combined With Standard of Care in Hospitalized and Nonhospitalized High-Risk Adolescents and Adults With Influenza A Infection
The Journal of Infectious Diseases · 2025
DOI: 10.1093/infdis/jiae408 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Lorant Leopold und 8 weiteren Autor:innen. Beteiligte Einrichtung: Janssen Research & Development, Titusville, New Jersey, USA. Hauptthemen laut MEDLINE: Influenza, Human, Antiviral Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Janssen, Biomedical Advanced Research and Development Authority.
Abstract (Originalsprache)
Background
An unmet need exists for effective antivirals to treat patients hospitalized with influenza. The results of 2 phase 3 studies that evaluated the efficacy and safety of pimodivir in combination with investigator-chosen standard of care (SoC) treatment are presented.
Methods
Hospitalized patients (hospital study; NCT03376321) and high-risk outpatients (outpatient study; NCT03381196) with laboratory-confirmed influenza A infection were randomized 1:1 to 600 mg pimodivir twice daily + SoC or placebo twice daily + SoC for 5 days. For most patients, SoC included oseltamivir. Primary end points were Hospital Recovery Scale (HRS) at day 6 (hospital study) and median time to resolution (TTR) of influenza-related symptoms (outpatient study).
Results
Pimodivir + SoC (oseltamivir) treatment showed no clinical benefit over placebo + SoC on HRS at day 6 (common odds ratio, 0.943; 95% confidence interval [CI], .609–1.462; P = .397; hospital study). A shorter median TTR of 7 symptoms was estimated with pimodivir + SoC versus placebo (92.6 hours; 95% CI, 77.6–104.2 vs 105.1 hours; 95% CI, 92.7–128.6; P = .0216; outpatient study).
Conclusions
Pimodivir + SoC showed no additional clinical benefit versus SoC treatment alone in hospitalized patients. Pimodivir + SoC demonstrated shorter TTR of influenza symptoms versus placebo + SoC in high-risk outpatients. Clinical Trial Registration NCT03376321 and NCT03381196.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Janssen Research & Development, Titusville, New Jersey, USA.
- Janssen Research & Development, Beerse, Belgium.
- Janssen Research & Development, Paris, France.
- Janssen Global Medical Affairs, IDV, Vienna, Austria.
- Janssen Research & Development, High Wycombe, UK.
ORCID-Profile: Lorant Leopold
Förderung
- Janssen
- Biomedical Advanced Research and Development Authority
Zitieren
APA
Leopold, L., Vingerhoets, J., Deleu, S., Nalpas, C., Weber, K., van Dromme, I., Lowson, D., Michiels, B., & van Duijnhoven, W. (2025). Efficacy and Safety of Pimodivir Combined With Standard of Care in Hospitalized and Nonhospitalized High-Risk Adolescents and Adults With Influenza A Infection. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae408
Vancouver
Leopold L, Vingerhoets J, Deleu S, Nalpas C, Weber K, van Dromme I, et al. Efficacy and Safety of Pimodivir Combined With Standard of Care in Hospitalized and Nonhospitalized High-Risk Adolescents and Adults With Influenza A Infection. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiae408
BibTeX
@article{Leopold2025,
author = {Leopold, Lorant and Vingerhoets, Johan and Deleu, Sofie and Nalpas, Catherine and Weber, Karin and van Dromme, Ilse and Lowson, David and Michiels, Bart and van Duijnhoven, Wilbert},
title = {Efficacy and Safety of Pimodivir Combined With Standard of Care in Hospitalized and Nonhospitalized High-Risk Adolescents and Adults With Influenza A Infection},
journal = {The Journal of Infectious Diseases},
year = {2025},
doi = {10.1093/infdis/jiae408}
}
EUVIMED